Budget impact analysis for three glucagon-like peptide-1 receptor agonist-based therapies for type 2 diabetes mellitus management in Saudi Arabia

References

• Ahmad E, Lim S, Lamptey R, et al. Type 2 diabetes. Lancet. 2022;400(10365):1803–1820. doi: 10.1016/S0140-6736(22)01655-5.
   PubMed Web of Science ®Google Scholar
• Hunt D, Hemmingsen B, Matzke A, et al. The WHO Global Diabetes Compact: a new initiative to support people living with diabetes. Lancet Diabetes Endocrinol. 2021;9(6):325–327. doi: 10.1016/S2213-8587(21)00111-X.
   PubMed Web of Science ®Google Scholar
• Alzaid A, Ladrón de Guevara P, Beillat M, et al. Burden of disease and costs associated with type 2 diabetes in emerging and established markets: systematic review analyses. Expert Rev Pharmacoecon Outcomes Res. 2021;21(4):785–798. doi: 10.1080/14737167.2020.1782748.
   PubMed Web of Science ®Google Scholar
• Aljulifi MZ. Prevalence and reasons of increased type 2 diabetes in Gulf Cooperation Council Countries. Saudi Med J. 2021;42(5):481–490. doi: 10.15537/smj.2021.42.5.20200676.
   PubMed Web of Science ®Google Scholar
• Alwadeai KS, Alhammad SA. Prevalence of type 2 diabetes mellitus and related factors among the general adult population in Saudi Arabia between 2016–2022: a systematic review and meta-analysis of the cross-sectional studies. Medicine (Baltimore). 2023;102(24):e34021. doi: 10.1097/MD.0000000000034021.
   PubMed Web of Science ®Google Scholar
• Abu-Farha M, Tuomilehto J, Abubaker J. Editorial: diabetes in the Middle East. Front Endocrinol (Lausanne). 2021;12:638653. Available from: 10.3389/fendo.2021.638653
   PubMed Web of Science ®Google Scholar
• Cannon A, Handelsman Y, Heile M, et al. Burden of illness in type 2 diabetes mellitus. J Manag Care Spec Pharm. 2018;24(9-a Suppl):S5–S13. doi: 10.18553/jmcp.2018.24.9-a.s5.
   PubMed Web of Science ®Google Scholar
• Fowler MJ. Microvascular and macrovascular complications of diabetes. Clin Diabetes. 2008;26(2):77–82. doi: 10.2337/diaclin.26.2.77.
   Google Scholar
• Einarson TR, Acs A, Ludwig C, et al. Economic burden of cardiovascular disease in type 2 diabetes: a systematic review. Value Health. 2018;21(7):881–890. doi: 10.1016/j.jval.2017.12.019.
   PubMed Web of Science ®Google Scholar
• Bain SC, Cummings MH, McKay GA. Multidisciplinary approach to management and care of patients with type 2 diabetes mellitus. EMJ Diabet. 2019;71:73–81. doi: 10.33590/emjdiabet/10314374.
   Google Scholar
• Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753–2786. doi: 10.2337/dci22-0034.
   PubMed Web of Science ®Google Scholar
• Joseph JJ, Deedwania P, Acharya T, et al. Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the American Heart Association. Circulation. 2022;145(9):e722–e759. doi: 10.1161/CIR.0000000000001040.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association Professional Practice Committee. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes – 2024. Diabetes Care. 2023;47(Suppl 1):S158–S178. doi: 10.2337/dc24-S009.
   Google Scholar
• American Diabetes Association Professional Practice Committee. 10. Cardiovascular disease and risk management: standards of care in diabetes – 2024. Diabetes Care. 2023;47(Supplement_1):S179–S218.
   Google Scholar
• Almandoz JP, Lingvay I, Morales J, et al. Switching between glucagon-like peptide-1 receptor agonists: rationale and practical guidance. Clin Diabetes. 2020;38(4):390–402. Oct 1 doi: 10.2337/cd19-0100.
   PubMedGoogle Scholar
• Kristensen SL, Rørth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7(10):776–785. Oct doi: 10.1016/S2213-8587(19)30249-9.
   PubMed Web of Science ®Google Scholar
• Vergès B, Aboyans V, Angoulvant D, et al. Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms. Cardiovasc Diabetol. 2022;21(1):242. Nov 15 doi: 10.1186/s12933-022-01686-3.
   PubMed Web of Science ®Google Scholar
• Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–1844. Nov 10 doi: 10.1056/NEJMoa1607141.
   PubMed Web of Science ®Google Scholar
• Evans LM, Mellbin L, Johansen P, et al. A population-adjusted indirect comparison of cardiovascular benefits of once-weekly subcutaneous semaglutide and dulaglutide in the treatment of patients with type 2 diabetes, with or without established cardiovascular disease. Endocrinol Diabetes Metab. 2021;4(3):e00259.
   PubMedGoogle Scholar
• Nova Nordisk. T2DM Market Research, KSA. 2023.
   Google Scholar
• Bhagavathula AS, Vidyasagar K, Tesfaye W. Efficacy and safety of tirzepatide in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized phase II/III trials. Pharmaceuticals (Basel). 2021;14(10):991. doi: 10.3390/ph14100991.
   PubMedGoogle Scholar
• Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503–515. 5 doi: 10.1056/NEJMoa2107519.
   PubMed Web of Science ®Google Scholar
• Almalki Z, Alatawi Y, Alharbi A, et al. Cost-effectiveness of more intensive blood pressure treatment in patients with high risk of cardiovascular disease in Saudi Arabia: a modelling study of meta-analysis. Int J Hypertens. 2019;2019:6019401–6019409. doi: 10.1155/2019/6019401.
   PubMed Web of Science ®Google Scholar
• Brennan VK, Colosia AD, Copley-Merriman C, et al. Incremental costs associated with myocardial infarction and stroke in patients with type 2 diabetes mellitus: an overview for economic modeling. J Med Econ. 2014;17(7):469–480. doi: 10.3111/13696998.2014.915847.
   PubMedGoogle Scholar
• Al-Jedai AH, Almudaiheem HY, Alissa DA, et al. Cost of cardiovascular diseases and renal complications in people with type 2 diabetes mellitus in the Kingdom of Saudi Arabia: a retrospective analysis of claims database. PLoS One. 2022;17(10):e0273836. doi: 10.1371/journal.pone.0273836.
   PubMed Web of Science ®Google Scholar
• Sattar N, McGuire DK, Pavo I, et al. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nat Med. 2022;28(3):591–598. doi: 10.1038/s41591-022-01707-4.
   PubMed Web of Science ®Google Scholar
• Evans M, Berry S, Nazeri A, et al. The challenges and pitfalls of incorporating evidence from cardiovascular outcomes trials in health economic modelling of type 2 diabetes. Diabetes Obes Metab. 2023;25(3):639–648. doi: 10.1111/dom.14917.
   PubMed Web of Science ®Google Scholar
• 125469s036lbl.pdf [Internet]. [cited 2023 Jul 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125469s036lbl.pdf
   Google Scholar
• 209637s009lbl.pdf [Internet]. [cited 2023 Jul 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209637s009lbl.pdf
   Google Scholar
• ozempic-epar-summary-public_en.pdf [Internet]. [cited 2023 Jul 23]. Available from: https://www.ema.europa.eu/en/documents/overview/ozempic-epar-summary-public_en.pdf
   Google Scholar
• Guan R, Yang Q, Yang X, et al. Efficacy and safety of tirzepatide in patients with type 2 diabetes mellitus: a Bayesian network meta-analysis. Front Pharmacol. 2022;13:998816. doi: 10.3389/fphar.2022.998816.
   PubMedGoogle Scholar
• Vadher K, Patel H, Mody R, et al. Efficacy of tirzepatide 5, 10 and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: an adjusted indirect treatment comparison. Diabetes Obes Metab. 2022;24(9):1861–1868. doi: 10.1111/dom.14775.
   PubMed Web of Science ®Google Scholar
• ICER_Type-2-Diabetes_12-Month_Check-Up_03312023.pdf [Internet]. [cited 2023 Jul 4]. Available from: https://icer.org/wp-content/uploads/2021/06/ICER_Type-2-Diabetes_12-Month_Check-Up_03312023.pdf
   Google Scholar
• pbac-web-outcomes-07-2023-v2.pdf [Internet]. [cited 2023 Sep 12]. Available from: https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/pbac-outcomes/2023-07/pbac-web-outcomes-07-2023-v2.pdf
   Google Scholar
• Santulli G. Tirzepatide versus semaglutide once weekly in type 2 diabetes. N Engl J Med. 2022;386(7):e17.
   PubMed Web of Science ®Google Scholar
• Levi J, Wang J, Venter F, et al. Estimated minimum prices and lowest available national prices for antiobesity medications: improving affordability and access to treatment. Obesity (Silver Spring). 2023;31(5):1270–1279. doi: 10.1002/oby.23725.
   PubMed Web of Science ®Google Scholar
• Al-Omar HA, Aljuffali IA, Solà-Morales O. Value drivers for pharmaceutical products in health technology assessment (HTA) in Saudi Arabia: results from a capacity building, multi-stakeholder workshop. Saudi Pharm J. 2021;29(9):946–954. doi: 10.1016/j.jsps.2021.08.001.
   PubMed Web of Science ®Google Scholar
• Al-Omar HA, Attuwaijri AA, Aljuffali IA. Pharmaceutical companies’ views on a health technology assessment (HTA) entity in Saudi Arabia. Saudi Pharm J. 2020;28(6):662–668. doi: 10.1016/j.jsps.2020.04.006.
   PubMed Web of Science ®Google Scholar
• Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health. 2014;17(1):5–14. doi: 10.1016/j.jval.2013.08.2291.
   PubMed Web of Science ®Google Scholar
• Saudi Arabia diabetes report 2000 – 2045 [Internet]. [cited 2023 Jun 21]. Available from: https://diabetesatlas.org/data/
   Google Scholar
• Hansen BB, Nuhoho S, Ali SN, et al. Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis. J Med Econ. 2020;23(6):650–658. doi: 10.1080/13696998.2020.1722678.
   PubMed Web of Science ®Google Scholar
• Decision modelling for health economic evaluation – Health Economics Research Centre (HERC) [Internet]. [cited 2023 Jul 4]. Available from: https://www.herc.ox.ac.uk/downloads/decision-modelling-for-health-economic-evaluation
   Google Scholar
• Raghavan S, Vassy JL, Ho YL, et al. Diabetes mellitus-related all-cause and cardiovascular mortality in a national cohort of adults. J Am Heart Assoc. 2019;8(4):e011295.
   PubMed Web of Science ®Google Scholar
• Kothari V, Stevens RJ, Adler AI, et al. UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke. 2002;33(7):1776–1781. doi: 10.1161/01.str.0000020091.07144.c7.
   PubMed Web of Science ®Google Scholar
• Mulnier HE, Seaman HE, Raleigh VS, et al. Risk of myocardial infarction in men and women with type 2 diabetes in the UK: a cohort study using the General Practice Research Database. Diabetologia. 2008;51(9):1639–1645. doi: 10.1007/s00125-008-1076-y.
   PubMed Web of Science ®Google Scholar
• Pratley RE, Aroda VR, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018;6(4):275–286. doi: 10.1016/S2213-8587(18)30024-X.
   PubMed Web of Science ®Google Scholar
• Alqahtani SA, Al-Omar HA, Alshehri A, et al. Obesity burden and impact of weight loss in Saudi Arabia: a modelling study. Adv Ther. 2023;40(3):1114–1128. 1 doi: 10.1007/s12325-022-02415-8.
   PubMed Web of Science ®Google Scholar
• Almutairi N, Alkharfy KM. Direct medical cost and glycemic control in type 2 diabetic Saudi patients. Appl Health Econ Health Policy. 2013;11(6):671–675. doi: 10.1007/s40258-013-0065-6.
   PubMedGoogle Scholar
• NUPCO (National Unified Procurement Company). 2023 [cited 2023 Jul 4]. Available from: https://www.nupco.com/
   Google Scholar
• Consumer Price Index | General Authority for Statistics. [Internet]. [cited 2023 Jul 4]. Available from: https://www.stats.gov.sa/en/394
   Google Scholar
• Hartfiel N, Edwards RT. Cost–consequence analysis of public health interventions. In: Tudor Edwards R, McIntosh E, editors. Applied health economics for public health practice and research [Internet]. Oxford (UK): Oxford University Press; 2019 [cited 2023 Jul 4]. Available from: doi: 10.1093/med/9780198737483.003.0010.
   Google Scholar
• Mauskopf JA, Paul JE, Grant DM, et al. The role of cost-consequence analysis in healthcare decision-making. Pharmacoeconomics. 1998;13(3):277–288. doi: 10.2165/00019053-199813030-00002.
   PubMed Web of Science ®Google Scholar
• GOV.UK [Internet]. [cited 2023 Jul 4]. Cost consequence analysis: health economic studies. Available from: https://www.gov.uk/guidance/cost-consequence-analysis-health-economic-studies
   Google Scholar
• Reitzel SB, Bøgelund M, Basse A, et al. Semaglutide versus tirzepatide for people with type 2 diabetes: cost of glycemic control in Austria, The Netherlands, Lithuania, and the United Arab Emirates. Curr Med Res Opin. 2023;39(8):1055–1060. doi: 10.1080/03007995.2023.2231275.
   PubMed Web of Science ®Google Scholar
• Pratley RE, Catarig A, Lingvay I, et al. An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg. Diabetes Obes Metab. 2021;23(11):2513–2520. doi: 10.1111/dom.14497.
   PubMed Web of Science ®Google Scholar
• Alkhatib NS, Almutairi AR, Alkhezi OS, et al. Economic analysis of glucagon like peptide-1 receptor agonists from the Saudi Arabia payer perspective. Saudi Pharm J. 2022;30(4):433–439. doi: 10.1016/j.jsps.2022.01.018.
   PubMed Web of Science ®Google Scholar
• NICE. More evidence needed to recommend Type 2 diabetes treatment tirzepatide | News | News. NICE; 2023 [cited 2023 Jul 13]. Available from: https://www.nice.org.uk/news/article/more-evidence-needed-to-recommend-type-2-diabetes-treatment-tirzepatide
   Google Scholar
• Tirzepatide for treating type 2 diabetes.pdf [Internet]. [cited 2023 Nov 1]. Available from: https://www.nice.org.uk/guidance/ta924/resources/tirzepatide-for-treating-type-2-diabetes-pdf-82615547603653
   Google Scholar
• draft-guidance-consultation-committee-papers-pdf-13193620813.pdf [Internet]. [cited 2023 Nov 1]. Available from: https://www.nice.org.uk/guidance/ta924/evidence/draft-guidance-consultation-committee-papers-pdf-13193620813
   Google Scholar
• Leiter LA, Bain SC, Hramiak I, et al. Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial. Cardiovasc Diabetol. 2019;18(1):73. doi: 10.1186/s12933-019-0871-8.
   PubMedGoogle Scholar
• Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121–130. doi: 10.1016/S0140-6736(19)31149-3.
   PubMed Web of Science ®Google Scholar
• Aljabri KS, Bokhari SA, Aljabri BK. Hypertension in Saudi adults with type 2 diabetes. Interv Obes Diabetes. 2018;1(4):1–5.
   Google Scholar
• Alzaheb RA, Altemani AH. Prevalence and associated factors of dyslipidemia among adults with type 2 diabetes mellitus in Saudi Arabia. Diabetes Metab Syndr Obes. 2020;13:4033–4040. doi: 10.2147/DMSO.S246068.
   PubMed Web of Science ®Google Scholar